Zhitong Finance App News, Zejing Pharmaceutical (688266.SH) issued an announcement. Recently, a randomized controlled key clinical trial of ZG006 (INN name: Alveltamig) single-drug injection with a class 1 new drug developed independently by the company to treat patients with advanced small cell lung cancer who have relapsed or progressed after platinum-containing chemotherapy and at least 1 other system treatment (third line and above) completed a pre-set mid-term analysis. The Independent Data Monitoring Committee (IDMC) determined that the trial had reached the intended main end point after reviewing the results. The company will submit a pre-BLA (Biologics License Application) communication application to the Drug Evaluation Center (CDE) of the China Drug Administration and accelerate the marketing process of injectable ZG006.

Zhitongcaijing · 1d ago
Zhitong Finance App News, Zejing Pharmaceutical (688266.SH) issued an announcement. Recently, a randomized controlled key clinical trial of ZG006 (INN name: Alveltamig) single-drug injection with a class 1 new drug developed independently by the company to treat patients with advanced small cell lung cancer who have relapsed or progressed after platinum-containing chemotherapy and at least 1 other system treatment (third line and above) completed a pre-set mid-term analysis. The Independent Data Monitoring Committee (IDMC) determined that the trial had reached the intended main end point after reviewing the results. The company will submit a pre-BLA (Biologics License Application) communication application to the Drug Evaluation Center (CDE) of the China Drug Administration and accelerate the marketing process of injectable ZG006.